Haemonetics (HAE) Competitors $76.18 -1.99 (-2.55%) As of 11:51 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock HAE vs. DXCM, HQY, LNTH, PODD, QTRX, SIBN, PEN, ZBH, ALGN, and MMSIShould you be buying Haemonetics stock or one of its competitors? The main competitors of Haemonetics include DexCom (DXCM), HealthEquity (HQY), Lantheus (LNTH), Insulet (PODD), Quanterix (QTRX), SiBone (SIBN), Penumbra (PEN), Zimmer Biomet (ZBH), Align Technology (ALGN), and Merit Medical Systems (MMSI). These companies are all part of the "medical" sector. Haemonetics vs. Its Competitors DexCom HealthEquity Lantheus Insulet Quanterix SiBone Penumbra Zimmer Biomet Align Technology Merit Medical Systems Haemonetics (NYSE:HAE) and DexCom (NASDAQ:DXCM) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation. Does the media prefer HAE or DXCM? In the previous week, DexCom had 10 more articles in the media than Haemonetics. MarketBeat recorded 23 mentions for DexCom and 13 mentions for Haemonetics. DexCom's average media sentiment score of 1.35 beat Haemonetics' score of 1.13 indicating that DexCom is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Haemonetics 4 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DexCom 18 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is HAE or DXCM more profitable? DexCom has a net margin of 12.90% compared to Haemonetics' net margin of 12.32%. DexCom's return on equity of 30.05% beat Haemonetics' return on equity.Company Net Margins Return on Equity Return on Assets Haemonetics12.32% 26.37% 9.22% DexCom 12.90%30.05%10.00% Which has more volatility and risk, HAE or DXCM? Haemonetics has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500. Comparatively, DexCom has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500. Do analysts rate HAE or DXCM? Haemonetics presently has a consensus price target of $97.30, indicating a potential upside of 27.72%. DexCom has a consensus price target of $98.50, indicating a potential upside of 18.25%. Given Haemonetics' stronger consensus rating and higher possible upside, research analysts clearly believe Haemonetics is more favorable than DexCom.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Haemonetics 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 2 Strong Buy rating(s) 3.00DexCom 0 Sell rating(s) 4 Hold rating(s) 15 Buy rating(s) 3 Strong Buy rating(s) 2.95 Do institutionals & insiders have more ownership in HAE or DXCM? 99.7% of Haemonetics shares are owned by institutional investors. Comparatively, 97.8% of DexCom shares are owned by institutional investors. 1.8% of Haemonetics shares are owned by company insiders. Comparatively, 0.3% of DexCom shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has higher valuation & earnings, HAE or DXCM? DexCom has higher revenue and earnings than Haemonetics. Haemonetics is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHaemonetics$1.36B2.69$167.68M$3.3123.02DexCom$4.15B7.87$576.20M$1.3462.16 SummaryDexCom beats Haemonetics on 12 of the 17 factors compared between the two stocks. Get Haemonetics News Delivered to You Automatically Sign up to receive the latest news and ratings for HAE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HAE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HAE vs. The Competition Export to ExcelMetricHaemoneticsMED PRODUCTS IndustryMedical SectorNYSE ExchangeMarket Cap$3.66B$10.36B$5.49B$20.44BDividend YieldN/A2.08%5.25%3.73%P/E Ratio23.0216.6027.1527.82Price / Sales2.6929.76375.3054.10Price / Cash10.7622.8437.5022.41Price / Book4.663.698.014.59Net Income$167.68M$235.43M$3.17B$982.91M7 Day Performance-0.87%2.04%4.06%0.29%1 Month Performance6.50%2.57%4.03%3.97%1 Year Performance-14.86%-13.90%30.13%11.48% Haemonetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HAEHaemonetics4.9075 of 5 stars$76.18-2.5%$97.30+27.7%-10.0%$3.66B$1.36B23.023,023Positive NewsAnalyst UpgradeAnalyst RevisionDXCMDexCom4.8812 of 5 stars$87.29+1.1%$98.50+12.8%-22.9%$33.85B$4.03B65.1410,300Positive NewsHQYHealthEquity3.7368 of 5 stars$104.76-0.1%$118.09+12.7%+23.0%$9.07B$1.20B39.733,120Analyst ForecastInsider TradeLNTHLantheus4.4714 of 5 stars$81.86+0.5%$130.50+59.4%-21.0%$5.64B$1.53B14.22700Positive NewsPODDInsulet4.2293 of 5 stars$314.18+0.4%$321.00+2.2%+50.5%$22.03B$2.07B56.513,900Positive NewsAnalyst ForecastQTRXQuanterix2.5293 of 5 stars$6.65flat$15.60+134.6%-55.9%$332.20M$137.42M0.00460SIBNSiBone4.5 of 5 stars$18.82+2.1%$22.50+19.6%+38.6%$785.39M$167.18M0.00350PENPenumbra4.8398 of 5 stars$256.00-0.2%$302.40+18.1%+35.8%$9.93B$1.19B77.944,500Analyst ForecastZBHZimmer Biomet4.9113 of 5 stars$91.23-0.3%$111.53+22.2%-11.0%$18.10B$7.68B11.6217,000Analyst ForecastALGNAlign Technology4.4814 of 5 stars$189.33+0.4%$241.25+27.4%-17.9%$13.66B$4.00B34.4920,945Positive NewsAnalyst ForecastMMSIMerit Medical Systems4.4264 of 5 stars$93.480.0%$109.11+16.7%+9.2%$5.53B$1.36B45.827,400Analyst Forecast Related Companies and Tools Related Companies DexCom Alternatives HealthEquity Alternatives Lantheus Alternatives Insulet Alternatives Quanterix Alternatives SiBone Alternatives Penumbra Alternatives Zimmer Biomet Alternatives Align Technology Alternatives Merit Medical Systems Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:HAE) was last updated on 7/11/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Haemonetics Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Haemonetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.